FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2388156719> ?p ?o ?g. }

• W2388156719 endingPage "5548" @default.
• W2388156719 startingPage "5548" @default.
• W2388156719 abstract "5548 Background: PLD activity in platinum-resistant OC is modest. B, with its activity in platinum(Plat)-sensitive and Plat-resistant patients (pts), has not been combined with PLD. PLD intratumoral concentrations, if affected by B, might be reflected in PLD PK. This phase II study of PLD + B was started in 2007 to accrue 48 pts, unless 4 serious (> grade 3) adverse events (AEs) supervened. Methods: Improvement in progression-free survival (PFS) at 6 m from 25 to 40% at 6 m in Plat-resistant OC is primary endpoint. PK of PLD alone at 1h, d 7 and d 21 (cycle 1) vs with B (cycle 2), safety, and response rates (RECIST and CA125 criteria) were secondary endpoints. Dosing: PLD 30 mg/m 2 followed by B 15 mg/kg on cycles 2–7 (with option to continue) d 1 every 3 w. Pts recurring within 6 m of platinum-based treatment for OC after < 3 prior regimens (but no PLD or B) were eligible. Exclusions: bowel obstruction, prior perforation, uncontrolled hypertension, or vascular disease. Hematologic, mucocutaneous and renal toxicities were evaluated prior to each cycle, MUGA scans every third cycle; disease status by CA125 and/or RECIST every third cycle. Results: 21 of 24 pts enrolled to date are evaluable. Median age is 65, range 52–83; most had 2 prior chemotherapy regimens. Median 6 (range 3–12) cycles were given with 6 off study with progression at 3–7 cycles. RECIST and CA125 responses are under review; in 11 pts with baseline CA125 of > 40 IU/mL, median increase was 31% by cycle 2; later falling to -57%. AEs did not exceed grade 3; hand-foot syndrome led to PLD dose reduction in 8 pts (33%); asymptomatic decreases in left ventricular ejection fraction (LVEF) >10% in 3 pts were noted, with treatment discontinuation in 1. The mean (±SEM) secondary PK parameter estimates for Cmax, AUC, and elimination half life were 4.5 ± 0.5 ug/mL, 651.7 ± 61 ug/mL x h, and 93.3 ± 19.7 h, respectively. Conclusions: Cycles 1 and 2 PLD PK do not differ. PLD + B is tolerable with PLD dose modifications. Declines in LVEF in 1 institution have uncertain causality. Midway into the trial, safety and time on study encourage completion for study primary endpoint. [Table: see text]" @default.
• W2388156719 created "2016-06-24" @default.
• W2388156719 creator A5007605375 @default.
• W2388156719 creator A5015251047 @default.
• W2388156719 creator A5019216768 @default.
• W2388156719 creator A5021752290 @default.
• W2388156719 creator A5047967898 @default.
• W2388156719 creator A5057498489 @default.
• W2388156719 creator A5062600036 @default.
• W2388156719 creator A5068302986 @default.
• W2388156719 creator A5087545302 @default.
• W2388156719 creator A5089486616 @default.
• W2388156719 date "2009-05-20" @default.
• W2388156719 modified "2023-10-16" @default.
• W2388156719 title "Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results" @default.
• W2388156719 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.5548" @default.
• W2388156719 hasPublicationYear "2009" @default.
• W2388156719 type Work @default.
• W2388156719 sameAs 2388156719 @default.
• W2388156719 citedByCount "3" @default.
• W2388156719 crossrefType "journal-article" @default.
• W2388156719 hasAuthorship W2388156719A5007605375 @default.
• W2388156719 hasAuthorship W2388156719A5015251047 @default.
• W2388156719 hasAuthorship W2388156719A5019216768 @default.
• W2388156719 hasAuthorship W2388156719A5021752290 @default.
• W2388156719 hasAuthorship W2388156719A5047967898 @default.
• W2388156719 hasAuthorship W2388156719A5057498489 @default.
• W2388156719 hasAuthorship W2388156719A5062600036 @default.
• W2388156719 hasAuthorship W2388156719A5068302986 @default.
• W2388156719 hasAuthorship W2388156719A5087545302 @default.
• W2388156719 hasAuthorship W2388156719A5089486616 @default.
• W2388156719 hasConcept C112705442 @default.
• W2388156719 hasConcept C126322002 @default.
• W2388156719 hasConcept C126894567 @default.
• W2388156719 hasConcept C141071460 @default.
• W2388156719 hasConcept C197934379 @default.
• W2388156719 hasConcept C203092338 @default.
• W2388156719 hasConcept C2776694085 @default.
• W2388156719 hasConcept C2777288759 @default.
• W2388156719 hasConcept C2777802072 @default.
• W2388156719 hasConcept C2778822529 @default.
• W2388156719 hasConcept C535046627 @default.
• W2388156719 hasConcept C71924100 @default.
• W2388156719 hasConcept C90924648 @default.
• W2388156719 hasConceptScore W2388156719C112705442 @default.
• W2388156719 hasConceptScore W2388156719C126322002 @default.
• W2388156719 hasConceptScore W2388156719C126894567 @default.
• W2388156719 hasConceptScore W2388156719C141071460 @default.
• W2388156719 hasConceptScore W2388156719C197934379 @default.
• W2388156719 hasConceptScore W2388156719C203092338 @default.
• W2388156719 hasConceptScore W2388156719C2776694085 @default.
• W2388156719 hasConceptScore W2388156719C2777288759 @default.
• W2388156719 hasConceptScore W2388156719C2777802072 @default.
• W2388156719 hasConceptScore W2388156719C2778822529 @default.
• W2388156719 hasConceptScore W2388156719C535046627 @default.
• W2388156719 hasConceptScore W2388156719C71924100 @default.
• W2388156719 hasConceptScore W2388156719C90924648 @default.
• W2388156719 hasIssue "15_suppl" @default.
• W2388156719 hasLocation W23881567191 @default.
• W2388156719 hasOpenAccess W2388156719 @default.
• W2388156719 hasPrimaryLocation W23881567191 @default.
• W2388156719 hasRelatedWork W1966541007 @default.
• W2388156719 hasRelatedWork W2051764329 @default.
• W2388156719 hasRelatedWork W209167384 @default.
• W2388156719 hasRelatedWork W2115848668 @default.
• W2388156719 hasRelatedWork W2153255824 @default.
• W2388156719 hasRelatedWork W2380991724 @default.
• W2388156719 hasRelatedWork W3197824728 @default.
• W2388156719 hasRelatedWork W3207313530 @default.
• W2388156719 hasRelatedWork W4226051264 @default.
• W2388156719 hasRelatedWork W1962564742 @default.
• W2388156719 hasVolume "27" @default.
• W2388156719 isParatext "false" @default.
• W2388156719 isRetracted "false" @default.
• W2388156719 magId "2388156719" @default.
• W2388156719 workType "article" @default.